Literature DB >> 21682943

Regionally selective activation and differential regulation of ERK, JNK and p38 MAP kinase signalling pathway by protein kinase C in mood modulation.

Nicoletta Galeotti1, Carla Ghelardini.   

Abstract

A growing body of evidence indicates that the extracellular signal-regulated kinase (ERK) pathway may participate in the neuronal modulation of depression. p38MAPK and c-Jun-N-terminal kinase/stress-activated protein kinase (JNK/SAPK) also belong to the MAPK family which mainly function as mediators of cellular stresses. Since increasing evidence implicates stress as an important factor in vulnerability to depressive illnesses, the involvement of ERK, JNK and p38MAPK pathways in the modulation of mood was investigated in the forced swim test (FST) and tail suspension test (TST). The effect produced by a single acute session of FST and TST on hippocampal and cortical MAPK expression and phosphorylation was investigated by immunoblotting experiments. In the hippocampus of animals exposed to FST and TST, an intensive, PKC-dependent, ERK1, ERK2, JNK, and p38MAPK phosphorylation was observed. In the frontal cortex, the FST and TST produced a PKC-dependent increase of ERK2 and p38MAPK phosphorylation, a PKC-independent activation of JNK and cAMP response element-binding protein (CREB) whereas any involvement of ERK1 was detected. The PKC blocker calphostin C (0.05-0.1 μg i.c.v.), the MEK inhibitor U0126 (10-20 μg i.c.v.), the p38MAPK inhibitor SB203580 (5-20 μg i.c.v.) and the JNK inhibitor II (0.5-5 μg i.c.v.), produced antidepressant-like behaviour without altering locomotor activity. These results illustrate a differentially mediated activation of MAPK in hippocampus and frontal cortex of animals exposed to behavioural despair paradigms. An antidepressant-like phenotype produced by acute blockade of MAPK signalling was also demonstrated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21682943     DOI: 10.1017/S1461145711000897

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  19 in total

1.  Vatairea macrocarpa lectin (VML) induces depressive-like behavior and expression of neuroinflammatory markers in mice.

Authors:  Filipe Marques Gonçalves; Andiara Espíndola Freitas; Tanara Vieira Peres; Débora Kurrle Rieger; Juliana Ben; Mariana Maestri; Ana Paula Costa; Ana Carolina Tramontina; Carlos Alberto Gonçalves; Ana Lúcia Severo Rodrigues; Celso Shiniti Nagano; Edson Holanda Teixeira; Kyria S Nascimento; Benildo Sousa Cavada; Rodrigo Bainy Leal
Journal:  Neurochem Res       Date:  2013-09-12       Impact factor: 3.996

Review 2.  Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents.

Authors:  Ronald S Duman; Bhavya Voleti
Journal:  Trends Neurosci       Date:  2012-01       Impact factor: 13.837

Review 3.  The ERK Pathway: Molecular Mechanisms and Treatment of Depression.

Authors:  John Q Wang; Limin Mao
Journal:  Mol Neurobiol       Date:  2019-02-09       Impact factor: 5.590

4.  Chronic social defeat up-regulates expression of norepinephrine transporter in rat brains.

Authors:  Ping Chen; Yan Fan; Ying Li; Zhongwen Sun; Garth Bissette; Meng-Yang Zhu
Journal:  Neurochem Int       Date:  2011-11-15       Impact factor: 3.921

5.  Upregulation of hippocampal extracellular signal-regulated kinase (ERK)-2 induces antidepressant-like behavior in the rat forced swim test.

Authors:  Sergio D Iñiguez; Lyonna F Parise; Mary Kay Lobo; Francisco J Flores-Ramirez; Israel Garcia-Carachure; Brandon L Warren; Alfred J Robison
Journal:  Behav Neurosci       Date:  2019-04       Impact factor: 1.912

6.  Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.

Authors:  Beverly M Francis; Jimao Yang; Enid Hajderi; Mary E Brown; Bernadeta Michalski; Joanne McLaurin; Margaret Fahnestock; Howard T J Mount
Journal:  Neuropsychopharmacology       Date:  2012-04-11       Impact factor: 7.853

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression.

Authors:  Milica J Jovicic; Iva Lukic; Marija Radojcic; Miroslav Adzic; Nadja P Maric
Journal:  Med Hypotheses       Date:  2015-06-02       Impact factor: 1.538

Review 9.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  Amygdala dynorphin/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress.

Authors:  Gui-Ying Zan; Xiang Sun; Yu-Jun Wang; Rui Liu; Chen-Yao Wang; Wei-Jia Du; Liu-Bin Guo; Jing-Rui Chai; Qing-Lin Li; Zhi-Qiang Liu; Jing-Gen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-05-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.